Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight ...
Zacks Investment Research on MSN
AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus
Amgen AMGN reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of ...
With a strong presence in Canada, Australia and New Zealand, Sandoz is committed to helping millions of patients access critical and potentially life-changing biologic medicines sustainably and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results